We investigated the effects of simvastatin adjunctive therapy on the negative symptoms of schizophrenia. In this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4-6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. The Positive and Negative Syndrome Scale was used to measure the negative, positive, and general symptoms of schizophrenia at baseline and every 2 weeks. The Hamilton Depression Rating Scale and the Extrapyramidal Symptom Rating Scale were used to measure depression and extrapyramidal symptoms at baseline and week 8. Difference in change in negative symptoms score from the baseline to week 8 was considered the single primary outcome. At baseline, negative symptoms scores were higher than positive symptoms scores in both simvastatin and placebo groups. There was no baseline difference between the two groups in terms of any of the measured variables. Compared with the placebo group, the simvastatin group showed a significantly higher reduction in negative symptoms scores from baseline to week 8 [mean difference: 95% confidence interval=-1.42 (-2.32 to -0.52), P=0.003]. Similar findings were observed for total scores [mean difference: 95% confidence interval=-1.85 (-2.87 to -0.83), P=0.001]. The results were not significant for positive symptoms or general psychopathology scores. We found a favorable effect of simvastatin on negative symptoms of patients with schizophrenia; however, future studies are warranted to confirm these results.

中文翻译：

---

辛伐他汀辅助治疗精神分裂症阴性症状的随机双盲安慰剂对照试验。

我们调查了辛伐他汀辅助治疗对精神分裂症阴性症状的影响。在这项双盲试验中，患有慢性精神分裂症的住院患者在研究前至少用稳定剂量的利培酮稳定了至少4周，然后随机接受利培酮（4-6 mg /天）加辛伐他汀（40 mg /天（n = 33）或安慰剂（n = 33）8周。阳性和阴性综合征量表用于在基线和每两周测量一次精神分裂症的阴性，阳性和一般症状。汉密尔顿抑郁量表和锥体束外症状量表用于测量基线和第8周时的抑郁和锥体外系症状。从基线到第8周阴性症状得分变化的差异被认为是唯一的主要结局。在基线时 辛伐他汀组和安慰剂组的阴性症状评分均高于阳性症状评分。就任何测量变量而言，两组之间没有基线差异。与安慰剂组相比，辛伐他汀组从基线到第8周的阴性症状得分明显降低[平均差异：95％置信区间= -1.42（-2.32至-0.52），P = 0.003]。总分也观察到类似的发现[平均差异：95％置信区间= -1.85（-2.87至-0.83），P = 0.001]。结果对于阳性症状或一般精神病理学分数均不显着。我们发现辛伐他汀对精神分裂症患者的阴性症状有良好的作用。但是，有必要进行进一步的研究来证实这些结果。